Donald Olds - 08 Oct 2026 Form 4 Insider Report for Retension Pharmaceuticals, Inc.

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 08 Oct 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 08 Oct 2026, 21:39:23 UTC
Prior SEC filing: 05 Sep 2023
Source filing: View source filing
Reporting owner signature: /s/ Alex Schwartz, Attorney-in-fact

Key filing fact

Donald Olds filed Form 4 for Retension Pharmaceuticals, Inc. on 08 Oct 2026.

Key facts

This page summarizes Donald Olds's Form 4 filing for Retension Pharmaceuticals, Inc..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 08 Oct 2026, 21:39.

Change

Previous filing in this sequence was filed on 05 Sep 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001807762 Primary reporting owner

Olds Donald

Relationship: Director
Address: 1104 WEST BROAD STREET, SUITE 1029, FALLS CHURCH
Signature: /s/ Alex Schwartz, Attorney-in-fact
Signature date: 08 Oct 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

No ticker transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +5,636
Change %
Price: $0.000000^*
Shares after: 5,636
Date: 08 Oct 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 5,636
Exercise price: $12.00
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Option award granted pursuant to the Issuer's 2026 Equity Incentive Plan. Twenty-five percent of the stock option vests on the first anniversary of the date of grant, with the remaining stock options vesting in 12 quarterly increments thereafter, subject to the Reporting Person's continued service to the Issuer on each vesting date.